155 related articles for article (PubMed ID: 20571233)
1. Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor.
Callesen AK; Madsen JS; Iachina M; Vach W; Kruse TA; Jensen ON; Mogensen O
Cancer Biomark; 2010; 6(2):73-82. PubMed ID: 20571233
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
[TBL] [Abstract][Full Text] [Related]
4. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
[TBL] [Abstract][Full Text] [Related]
5. IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2535-6. PubMed ID: 10470190
[TBL] [Abstract][Full Text] [Related]
6. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
7. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
[TBL] [Abstract][Full Text] [Related]
8. Characterization of serum biomarkers for detection of early stage ovarian cancer.
Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
[TBL] [Abstract][Full Text] [Related]
9. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
[TBL] [Abstract][Full Text] [Related]
10. [Identification of serum biomarkers for ovarian cancer using protein chips and time of flight mass spectrometry technology].
Wang Q; Li L; Li DR; Zhang W; Wei X; Zhang JQ; Tang Y
Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):544-8. PubMed ID: 17083841
[TBL] [Abstract][Full Text] [Related]
11. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
Podnos YD; Gamboa G; Kurosaki T; Buller R; Walker JL; Manetta A
Gynecol Oncol; 1997 Jul; 66(1):71-4. PubMed ID: 9234924
[TBL] [Abstract][Full Text] [Related]
12. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
13. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry.
Callesen AK; Christensen Rd; Madsen JS; Vach W; Zapico E; Cold S; Jørgensen PE; Mogensen O; Kruse TA; Jensen ON
Rapid Commun Mass Spectrom; 2008; 22(3):291-300. PubMed ID: 18181248
[TBL] [Abstract][Full Text] [Related]
15. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
16. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
[TBL] [Abstract][Full Text] [Related]
17. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
[TBL] [Abstract][Full Text] [Related]
18. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
20. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
